EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 107.96

Change

-1.96 (-1.78)%

Market Cap

USD 0.70B

Volume

2.57K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.28 (-0.55%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.50%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.13 (-0.47%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.17 (-0.67%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.27 (-0.61%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

+1.38 (+1.00%)

USD 102.09B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.26 (-0.51%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.19 (-0.18%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.32 (-0.22%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.22% 46% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.22% 46% F 45% F
Trailing 12 Months  
Capital Gain -0.81% 13% F 22% F
Dividend Return 1.38% 24% F 20% F
Total Return 0.57% 16% F 24% F
Trailing 5 Years  
Capital Gain 16.78% 47% F 52% F
Dividend Return 8.04% 50% F 38% F
Total Return 24.82% 50% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 7.07% 53% F 53% F
Dividend Return 8.08% 55% F 55% F
Total Return 1.00% 70% C- 49% F
Risk Return Profile  
Volatility (Standard Deviation) 8.26% 69% C- 76% C+
Risk Adjusted Return 97.83% 87% B+ 88% B+
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike